Targeting EGFR degradation by autophagosome degraders
- 26 March 2024
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 270, 116345
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 34 references indexed in Scilit:
- Emerging New Concepts of Degrader TechnologiesTrends in Pharmacological Sciences, 2020
- Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomideBioorganic & Medicinal Chemistry Letters, 2020
- Design and synthesis of selective degraders of EGFRL858R/T790M mutantEuropean Journal of Medicinal Chemistry, 2020
- AUTACs: Cargo-Specific Degraders Using Selective AutophagyMolecular Cell, 2019
- Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor ReceptorJournal of Thoracic Oncology, 2019
- The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case StudyCell Chemical Biology, 2018
- Endocytic control of signaling at the plasma membraneCurrent Opinion in Cell Biology, 2016
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyThe Lancet Oncology, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007